References
- Alford C., Jr, Stagno S., Reynolds D. W. Congenital toxoplasmosis: clinical, laboratory, and therapeutic considerations, with special reference to subclinical disease. Bulletin of the New York Academy of Medicine 1974; 50: 160–181
- Commission of the European Communities. In vitro diagnostic medical devices. 1992, DGIII/D/4041/92‐EN and later versions
- Couvreur J., Desmonts G., Aron‐Rosa D. Ocular prognosis in congenital toxoplasmosis: the role of treatment. Preliminary communication. Annates de Pediatrie 1984; 31: 855–858
- Desmonts G., Couvreur J. Congenital toxoplasmosis. Prospective study of the outcome of pregnancy in 542 women with toxoplasmosis acquired during pregnancy. Annates de Pediatrie 1984; 31: 805–809
- Dutton G. N. Toxoplasmic retinochoroiditis–a historical review and current concepts. Annals of the Academy of Medicine (Singapore) 1989; 18: 214–221
- Koppe J. G., Loewer‐Sieger D. H., de‐Roever‐Bonnet H. Results of 20‐year follow‐up of congenital toxoplasmosis. Lancet 1966; i: 254–256
- Lebech M., Petersen E. Congenital toxoplasmosis. Scandinavian Journal of Infectious Diseases 1992; 84: 1–96, (supplement)
- Martin W. G., Brown G. C., Parrish R. K., Kimball R., Naidoff M. A., Benson W. E. Ocular toxoplasmosis and visual field defects. American Journal of Ophthalmology 1980; 90: 25–29
- Piens M. A., Garin J. P. New perspectives in the chemoprophylaxis of toxoplasmosis. Journal of Chemotherapy 1989; 1: 46–51
- Remington J. S., Desmonts G. Infectious Diseases of the Fetus and Newborn Child, J. S. Remington, J. O. Klein. W B Saunders, London 1990; 90–195
- van‐Druten H., van‐Knapen F., Reintjes A. Epidemiologic implications of limited‐duration seropositivity after toxoplasma infection. American Journal of Epidemiology 1990; 132: 169–180
- Wilson C. B., Remington J. S., Stagno S., Reynolds D. W. Development of adverse sequelae in children born with subclinical congenital. Toxoplusmu infection. Pediarrics 1980; 66: 767–774
- World Health Organization. 1989, Report of a WHO Workshop on Public Health Aspects of Toxoplasmosis. VPH/IC/90.1 (Annex 1)